Institutional-grade capital advisory built around two verticals. Healthcare and AI/technology — in depth, not in passing.
Healthcare is not a single market. It is a collection of sub-sectors — each with its own regulatory framework, reimbursement landscape, clinical development timeline, and investor base. Advisory firms that treat healthcare as a monolith do not serve their clients well. We have built our practice around the specific dynamics of each sub-vertical, and we apply that knowledge at every stage of a mandate — from positioning to investor targeting to negotiation.
Medical device companies face a capital formation challenge that is uniquely complex: they must fund product development, clinical trials, regulatory clearance, and commercial launch — often with limited recurring revenue during the most capital-intensive phases. We advise MedTech companies at every stage of this journey. We understand the FDA 510(k) and PMA pathways, the CE marking process for European market entry, and how institutional investors underwrite MedTech risk at seed, Series A, and growth stages. We have experience with implantables, surgical systems, neuromodulation devices, diagnostics hardware, and point-of-care technologies.
Relevant transactions: Seed equity · Series A–C · Venture debt for commercial-stage · M&A sell-side
Biotech financing requires advisors who understand how clinical data translates into investor conviction — and how to position a company's pipeline relative to competitive programs, regulatory precedent, and market size. We advise biotech companies across modalities including small molecules, biologics, cell and gene therapy, RNA therapeutics, and platform-based approaches. We understand how institutional biotech investors evaluate Phase I/II data packages, what a pre-IND financing looks like versus a post-Phase II raise, and how to structure a dual-track process that keeps both equity and strategic options open.
Relevant transactions: Pre-IND equity · Clinical-stage raises · Pharma partnership · Out-licensing · M&A sell-side
Digital health is the most rapidly evolving sub-sector in healthcare, and the capital market for it has matured significantly. Early-stage digital health investors now expect demonstration of clinical utility, payer reimbursement strategy, and enterprise sales traction — not just a consumer-facing product. We advise digital health companies that have moved beyond the idea stage and are raising capital to scale commercially. We understand the reimbursement landscape, the health system sales cycle, and what investors in this space require before writing a check.
Relevant transactions: Series A–C · Revenue-based financing · Strategic partnership with health systems or payers · M&A
The life science tools and instrumentation market serves academic, biopharma, and clinical research customers — a diverse buyer base with distinct procurement dynamics and budget cycles. We advise companies developing analytical instruments, laboratory automation systems, reagents and consumables, and research services platforms. We understand the distinction between academic market penetration and biopharma enterprise sales, and how investors value the recurring revenue characteristics of a consumables-heavy business model.
Relevant transactions: Series A–C · Growth equity · M&A sell-side · Strategic acquirer process
Radiopharmaceuticals represent one of the most compelling convergence plays in healthcare — combining nuclear medicine, oncology, and precision targeting in a modality that has attracted significant strategic interest from large pharma. We advise companies developing diagnostic and therapeutic radiopharmaceuticals, with an understanding of the manufacturing complexity, isotope supply chain constraints, and regulatory pathway that define this space. Our work in radiopharma spans equity financing, pharma licensing transactions, and sell-side M&A.
Relevant transactions: Clinical-stage equity · Pharma out-licensing · Strategic partnership · M&A sell-side
Healthcare services businesses — including specialty clinics, home health platforms, behavioral health networks, and value-based care organizations — operate at the intersection of clinical delivery and business model innovation. We advise healthcare services companies on growth equity raises, debt financing for expansion, and M&A transactions including platform acquisitions and add-on strategies. We understand how payer mix, reimbursement rate exposure, and unit economics are evaluated by institutional investors and strategic acquirers in this segment.
Relevant transactions: Growth equity · Debt for expansion · Buy-side acquisition strategy · M&A sell-side
The AI and technology investment landscape is defined by a set of dynamics that reward deep familiarity: the pace of model development, the mechanics of data moat construction, the enterprise adoption cycle, and the structural factors that distinguish durable AI businesses from those built on temporary access to compute or foundational model capabilities. We focus on companies with defensible differentiation — and we advise them with an understanding of how sophisticated technology investors evaluate the stack, the team, and the go-to-market.
The infrastructure layer of the AI economy — including compute orchestration, data pipeline tooling, model training and inference optimization, and MLOps platforms — is attracting significant institutional capital as enterprise AI adoption accelerates. We advise AI infrastructure companies on equity raises at seed through growth stages, with an understanding of how investors differentiate between companies building genuine infrastructure and those providing point solutions with limited defensibility.
The convergence of AI and healthcare is generating a wave of company formation at the intersection of clinical data, machine learning, and regulatory science. We are active in this space and understand both sides of the equation — the healthcare buyer's requirements and the AI investor's expectations. We advise companies developing AI-powered diagnostic tools, clinical decision support systems, drug discovery platforms, and healthcare workflow automation solutions.
Enterprise software remains a core focus for institutional technology investors, and the metrics by which SaaS businesses are evaluated — ARR growth, net revenue retention, payback period, and CAC/LTV — are well understood by the investor base we cover. We advise enterprise SaaS companies on growth equity raises, structured debt facilities appropriate for SaaS revenue profiles, and M&A transactions including strategic acquirer processes and private equity-backed roll-ups.
The cybersecurity market is large, growing, and increasingly driven by enterprise compliance requirements and regulatory pressure — dynamics that create durable demand for companies with proven solutions. We advise cybersecurity companies across endpoint security, identity governance, network security, and security operations center (SOC) tooling. We understand how institutional cybersecurity investors evaluate competitive differentiation, enterprise customer concentration, and the regulatory tailwinds that support long-term growth.
Defense technology — spanning autonomous systems, dual-use AI, secure communications, and advanced sensing — has attracted a new class of institutional investors as the strategic importance of technological superiority has been re-established in the national security context. We advise defense technology companies navigating the intersection of venture capital, government contracts, and strategic acquirer interest. We understand the ITAR environment, the OTA contracting process, and how to position a dual-use technology business for both commercial and government investor audiences.
A generalist advisor can introduce you to investors. A specialist advisor can tell you which investors are actually deploying into your sub-sector right now, what they paid for the last comparable company, what questions they are going to ask on the first call, and what is going to happen when their technical due diligence team reviews your clinical data or your AI architecture.
That difference — between introduction and informed guidance — is the difference between a process that takes eighteen months and ends in a down round, and one that takes four months and closes at a valuation that reflects the company's true potential.
Healthcare and AI are not simple markets. The regulatory frameworks are complex. The investor base is specialized and has long memories. The diligence process is rigorous and technical. And the consequences of a poorly run process — a missed milestone, a damaged investor relationship, a term sheet that looked good until the lawyers marked it up — are material.
Lucent Growth was built around the conviction that the companies operating in these sectors deserve advisors who are as specialized as they are. We do not cover twenty industries. We cover two. And we cover them in depth.
If you are building in healthcare or AI/technology and evaluating a capital raise or strategic transaction, we would like to understand your situation.
Request a Confidential DiscussionAll initial discussions are strictly confidential and carry no obligation.